Vorinostat for NSCLC: Not a home-run, but at least swinging for the fences

Article

Substantial resources are spent on large, expensive trials to demonstrate small survival advantages in lung cancer. For example, 889 patients entrusted their care to the phase III SATURN trial of maintenance erlotinib, following treatment with a platinum doublet. At ASCO, we learned that these patients were rewarded with a one week improvement in PFS, and at

Subscribe to HDACi